More about

Giant Cell Arteritis

News
October 12, 2020
2 min read
Save

Moving away from ‘failed’ prednisone to IL-6 blockade in giant cell arteritis

Moving away from ‘failed’ prednisone to IL-6 blockade in giant cell arteritis

Recent landmark study results have shown that interleukin-6 blockade may be superior to prolonged prednisone therapy in giant cell arteritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

News
September 28, 2020
2 min read
Save

No single sign, symptom adequate 'to rule in or rule out' giant cell arteritis

No single sign, symptom adequate 'to rule in or rule out' giant cell arteritis

Although no single sign or symptom alone is strong enough to confirm a diagnosis of giant cell arteritis, a collection of features, including limb claudication and temporal artery thickening, are most informative, according to findings published in JAMA Internal Medicine.

News
September 10, 2020
4 min read
Save

GCA, TAK likely react differently to tocilizumab, despite disease similarities

GCA, TAK likely react differently to tocilizumab, despite disease similarities

Although many rheumatologists view Takayasu’s arteritis as “basically the same disease” as giant cell arteritis, tocilizumab is more effective in the latter than the former, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.

News
April 15, 2020
6 min read
Save

Elderly man presents with bilateral decreased vision

Elderly man presents with bilateral decreased vision

An 83-year-old man presented to the New England Eye Center with a 2-week history of decreased vision in both eyes. He felt like letters were “clumping together,” making it difficult to read. He also complained that the inferior half of his vision in the right eye was foggy. He denied any new headaches, jaw claudication, transient visual obscurations, scalp tenderness, recent weight loss or fatigue. He was experiencing new gait instability and poor coordination.

News
March 23, 2020
2 min read
Save

Greater cumulative glucocorticoids dose confers risk for hypertension

Greater cumulative glucocorticoids dose confers risk for hypertension

High cumulative use of oral glucocorticoids was associated with excess incidence of hypertension, according to research published in the Canadian Medical Association Journal.

News
February 19, 2020
1 min read
Save

3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp - Best Of!

Immune-mediated inflammatory diseases (IMIDs) are a group of clinically heterogeneous disorders, including rheumatoid arthritis, psoriasis, psoriatic arthritis, giant cell arteritis, systemic lupus erythematosus, and axial spondyloarthritis, that share a similar immunopathology. Recognizing the underlying immunopathological mechanisms of these disorders is essential for understanding how current and emerging therapies exert their effects. In this CME activity, recorded during the Association of Women in Rheumatology National Conference, experts in the field examine common signaling pathways in IMIDs, evaluate recent clinical evidence for available and emerging immune-based therapies that target these pathways, assess the utilization of biomarkers for the identification of patients with early inflammatory disease, and evaluate the mechanisms of cancer immunotherapies as they relate to both an antitumor response and the potential for autoimmunity.

News
December 03, 2019
3 min read
Save

Symptoms, imaging abnormalities differ in patients with TAK, GCA

Symptoms, imaging abnormalities differ in patients with TAK, GCA

Among patients with Takayasu’s and giant cell arteritis, certain symptoms, such as carotidynia, are more closely associated with vascular inflammation based on 18F-fluorodeoxyglucose positron emission tomography, or FDG-PET, while claudication and other symptoms are more linked to vascular damaged based on magnetic resonance angiography, according to data published in the Annals of the Rheumatic Diseases.

News
November 14, 2019
3 min read
Save

Half of GCA patients receiving tocilizumab remained in remission 2 years after withdrawal

Half of GCA patients receiving tocilizumab remained in remission 2 years after withdrawal

ATLANTA — Approximately 47% of patients in clinical remission after receiving 1 year of weekly tocilizumab for giant cell arteritis maintained their treatment-free remission for an additional 2 years, according to a speaker at the 2019 ACR/ARP Annual Meeting.

News
November 14, 2019
2 min read
Save

Vasculitis guidelines support first-line biologic therapies in certain patients

Vasculitis guidelines support first-line biologic therapies in certain patients

ATLANTA — Increased use of glucocorticoid-sparing agents is one of the key recommendations in a guideline document that covers seven vasculitis diseases, according to a speaker at ACR/ARP 2019.

View more